Manufacturer
TAIWAN BIOTECH CO., LTD.
Contents
Ipratropium Bromide; Salbutamol Sulphate
Indication
Management of reversible bronchospasm associated w/ obstructive airway disease in patients who require more than a single bronchodilator.
Instruction
Adult including elderly Acute attacks 1 unit-dose vial. Severe cases May require 2nd unit-dose vial to be administered. Maintenance: 1 unit-dose vial tds or qds.
Drug interaction
Increased side effects w/ xanthine derivatives, other β-adrenergics & anticholinergics. Increased β2-agonist induced hypokalaemia w/ glucocorticosteroids & diuretics. Increased susceptibility to arrhythmia w/ digoxin. Potentially serious reduction in bronchodilator effects w/ β-blockers. Enhanced β-adrenergic agonists action w/ MAOIs & TCAs. Increased susceptibility to CV effects of β-agonists w/ halogenated hydrocarbon anaesth eg, halothane, trichloroethylene & enflurane.
Malaysia
